Skip to main content

Advertisement

Table 3 Treatment strategies used among patients with non-metastatic breast cancer

From: Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon

Variable Category Frequency (%)
Surgery Yes 258(99.2)
  No 2(0.8)
   260(100)
Type of surgery Radical mastectomy 187(72.5)
  Breast conserving surgery 71(27.5)
   258(100)
*Axillary lymph node dissection Yes 210(81.4)
  No 48(18.6)
   258(100)
Chemotherapy Yes 147(56.5)
  No 113(43.5)
   260(100)
Type Neoadjuvant 14(9.5)
  Adjuvant 107(72.8)
  Both 26(17.7)
   147(100)
Drug combination Cyclophosphamide + Doxorubicin + 5-Fluorouracil 120(82)
  Cyclophosphamide + Methotrexate + 5-Fluorouracil 7(4.8)
  Docetaxel + Doxorubicin + Cyclophosphamide 4(2.7)
  OTHERS 16(10.8)
  147(100)
Hormone therapy Yes 129(49.8)
  No 131(50.4)
Type Anastrozole 7(5.4)
  Tamoxifen 122(94.6)
   129(100)
Duration 5years 13(100)
Radiation therapy Yes 201(77.3)
  No 59(22.7)
   260(100)
Duration 5 weeks 178(88.6)
  6 weeks 20(10.0)
  9 weeks 2(1.0)
  10 weeks 1(0.5)
   201(100)
Treatment combination  
Surgery + chemotherapy + radiation therapy   66(25.7)
Surgery + chemotherapy + radiation therapy + hormonal therapy   63(24.1)
Surgery + radiation therapy + hormonal therapy   50(19.5)
Surgery alone   32(12.5)
Surgery + radiation therapy   20(7.8)
Surgery + chemotherapy   12(4.7)
Surgery + hormonal therapy   11(3.9)
Surgery + chemotherapy + hormonal therapy   6(2.0)
   260(100)
  1. The entries in boldface/italics represent the total case files for which information on the relevant variable was available